These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10029075)

  • 21. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
    Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
    Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis.
    Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Ishikawa S; Wada H
    Lung Cancer; 2003 Mar; 39(3):289-96. PubMed ID: 12609567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver.
    Ho JW; Poon RT; Sun CK; Xue WC; Fan ST
    World J Gastroenterol; 2005 Jan; 11(2):176-81. PubMed ID: 15633211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S; Zarkovic K; Eskinja N; Jonjic N
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression.
    Dales JP; Garcia S; Carpentier S; Andrac L; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
    Hum Pathol; 2004 Feb; 35(2):176-83. PubMed ID: 14991534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative prognostic relevance of breast intra-tumoral microvessel density evaluated by CD105 and CD146: A pilot study of 42 cases.
    Martinez LM; Labovsky V; Calcagno Mde L; Davies KM; Rivello HG; Wernicke A; Calvo JC; Chasseing NA
    Pathol Res Pract; 2016 Apr; 212(4):350-5. PubMed ID: 26872535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays.
    Charpin C; Dales JP; Garcia S; Carpentier S; Djemli A; Andrac L; Lavaut MN; Allasia C; Bonnier P
    Clin Cancer Res; 2004 Sep; 10(17):5815-9. PubMed ID: 15355911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endoglin (CD105) expression in endometrial carcinoma.
    Saad RS; Jasnosz KM; Tung MY; Silverman JF
    Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
    Gluz O; Wild P; Liedtke C; Kates R; Mendrik H; Ehm E; Artinger V; Diallo-Danebrock R; Ting E; Mohrmann S; Poremba C; Harbeck N; Nitz U; Hartmann A; Gaumann A
    Breast Cancer Res Treat; 2011 Apr; 126(3):643-51. PubMed ID: 21318601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
    Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
    Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34.
    Miyata Y; Sagara Y; Watanabe S; Asai A; Matsuo T; Ohba K; Hayashi T; Sakai H
    Virchows Arch; 2013 Nov; 463(5):673-9. PubMed ID: 23975255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
    Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
    Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different features of angiogenesis between ovarian and breast carcinoma.
    Nakayama K; Kanzaki A; Takebayashi Y; Toi M; Bando H; Nabei T; Miyazaki K; Fukumoto M
    Cancer Lett; 2001 Sep; 170(2):161-7. PubMed ID: 11463494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Association of microvessel density and blood vessel invasion with the prognosis in rectal carcinoma at stages I to II].
    Zhou YJ; Ye Q; Lu HS; Yang YH; Guan GX; Huang CM; Wang C; Zhang J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Jul; 13(7):516-9. PubMed ID: 20658366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer.
    Gómez-Esquer F; Agudo D; Martínez-Arribas F; Nuñez-Villar MJ; Schneider J
    Anticancer Res; 2004; 24(3a):1581-5. PubMed ID: 15274325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of microvessel density quantified through the immunohistochemistry expression of CD34 and CD105 in rectal cancer.
    Goldiş DS; Sferdian MF; Tarţă C; Fulger LO; Totolici BD; Neamţu C
    Rom J Morphol Embryol; 2015; 56(2):419-24. PubMed ID: 26193208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients.
    Dales JP; Garcia S; Bonnier P; Duffaud F; Andrac-Meyer L; Ramuz O; Lavaut MN; Allasia C; Charpin C
    Am J Clin Pathol; 2003 Mar; 119(3):374-80. PubMed ID: 12645339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of endoglin (CD105) expression in ovarian carcinoma.
    Taskiran C; Erdem O; Onan A; Arisoy O; Acar A; Vural C; Erdem M; Ataoglu O; Guner H
    Int J Gynecol Cancer; 2006; 16(5):1789-93. PubMed ID: 17009973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining.
    Ponzoni M; Savage DG; Ferreri AJ; Pruneri G; Viale G; Servida P; Bertolini F; Orazi A
    Mod Pathol; 2004 Dec; 17(12):1513-20. PubMed ID: 15272276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count.
    Romani AA; Borghetti AF; Del Rio P; Sianesi M; Soliani P
    J Surg Oncol; 2006 May; 93(6):446-55. PubMed ID: 16615157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.